Cymabay Therapeutics (CBAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Sales | 57 | 0 | 31,016 | 0 | 0 |
| Gross Profit | 57 | N/A | 31,016 | N/A | N/A |
| Operating Expenses | 42,555 | 32,207 | 31,115 | 26,875 | 23,477 |
| Operating Income | -42,498 | -32,207 | -99 | -26,875 | -23,477 |
| Interest Expense | 5,081 | 4,843 | 4,618 | 4,403 | 4,075 |
| Other Income | 5,677 | 3,168 | 3,909 | 2,500 | 919 |
| Pre-tax Income | -41,902 | -33,882 | -808 | -28,778 | -26,633 |
| Net Income Continuous | -41,902 | -33,882 | -808 | -28,778 | -26,633 |
| Net Income | $-41,902 | $-33,882 | $-808 | $-28,778 | $-26,633 |
| EPS Basic Total Ops | -0.37 | -0.32 | -0.01 | -0.29 | -0.30 |
| EPS Basic Continuous Ops | -0.37 | -0.32 | -0.01 | -0.29 | -0.30 |
| EPS Diluted Total Ops | -0.37 | -0.32 | -0.01 | -0.29 | -0.30 |
| EPS Diluted Continuous Ops | -0.37 | -0.32 | -0.01 | -0.29 | -0.30 |
| EPS Diluted Before Non-Recurring Items | -0.35 | -0.32 | -0.01 | -0.29 | -0.30 |
| EBITDA(a) | $-44,904 | $-34,086 | $-1,878 | $-27,994 | $-23,968 |